menu
    • menu
    [{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Australasian Leukaemia And Lymphoma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia And Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Arsenic Trioxide

    Menu

    Arsenic Trioxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : ABO Securities

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BioSenic Signs a New Subscription Agreement for a Maximum of EUR 1.2M in Convertible Bonds

                            Details : The proceeds from the financing will contribute to advancing clinical development of BioSenic’s lead asset its ATO product, Arscimed (arsenic trioxide), for treating chronic graft versus host disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : ABO Securities

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioSenic Releases New Analysis of Phase 2 Data for Arsenic Trioxide in cGvHD

                            Details : Arscimed (arsenic trioxide) is a thioredoxin reductase 1 inhibitor small molecule drug candidate, which is being evaluated for the treatment of chronic graft versus host disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : ABO Securities

                            Deal Size : $2.2 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioSenic Signs a New Subscription Agreement for a Maximum of EUR 2.1M in Convertible Bonds

                            Details : The proceeds of the financing will essentially contribute to continuing to advance the clinical development of Arscimed (arsenic trioxide) in the treatment of chronic graft versus host disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            June 21, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : ABO Securities

                            Deal Size : $2.2 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Phebra

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medsenic Subsidiary Signs Licensing Agreement with Phebra PTY Ltd

                            Details : Medsenic and Phebra should facilitate the final steps of manufacturing, clinical confirmation of efficacy and subsequent commercialization of oral ArsciCor (arsenic trioxide) in cGvHD.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 07, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Phebra

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Gestys Santé Biotech

                            Deal Size : $0.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioSenic Raises €500,000 in Private Placement of New Shares with Established New Investors

                            Details : BioSenic will use proceeds for a Phase 3 trial with Arscimed (oral arsenic trioxide) for first-line treatment of chronic graft-versus-host disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 02, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Gestys Santé Biotech

                            Deal Size : $0.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Phebra

                            Australia arrow
                            Pharma Live Expo
                            Not Confirmed

                            Phebra

                            Australia arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioSenic Reaches Agreement with Phebra on Oral Arsenic Trioxide Development for cGvHD

                            Details : The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.

                            Product Name : ArsciCor

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 15, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosenic Performs Further Analysis of its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Sc...

                            Details : ATO (arsenic trioxide) is administered daily by IV infusions, which is investigated for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 27, 2023

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medsenic

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Medsenic

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Phebra

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biosenic Provides Update Regarding Current License Agreement With Phebra

                            Details : Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            May 29, 2023

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Phebra

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide,Metal ion

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioSenic Receives Key European Patent From EPO, For Further Therapeutic Development in Cancer, Infectious and ...

                            Details : Arscimed® (arsenic trioxide), is a able to radically modify the autoimmune cascade and normalise the immune system without causing nonspecific immunosuppressionbeing studied for cGvHD.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Arsenic Trioxide,Metal ion

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bone Therapeutics

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed

                            Bone Therapeutics

                            Belgium arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acqui...

                            Details : The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth